



BSW Formulary Updates and Recent Decisions – October 2024

New additions to BSWformulary and Change in Traffic Light Status (TLS)

- [Parecoxib 40mg powder for solution for injection](#) - Added with a **RED** TLS as an alternative parenteral NSAID analgesic for palliative care patients under specialist supervision.
- [Esomeprazole 40mg powder for solution for injection](#) Added with a **RED** TLS for (off-label) subcutaneous use on the recommendation of palliative care specialist where PPI is necessary for symptomatic treatment and where oral access is unavailable.
- [Rimegepant](#) and [atogepant](#) for migraine prevention – TLS changed from **RED** to **AMBER** to allow prescribing to be taken over by GP's following specialist initiation. Also see [BSW Chronic Migraine Prevention Pathway](#)

New and Updated Prescribing Guidelines and Shared Care Agreements

- **UPDATE** – [BSW SCA Riluzole for adults](#) – Orodispersible film formulation added to SCA which presents a cost saving in primary care. Orodispersible film is first line on BSW formulary and patients in primary care being prescribed tablets can be switched to Orodispersible film. Do not switch patients using riluzole liquid without seeking specialist advice.
- **UPDATE** – [BSW SCA Valproate for women of childbearing potential](#) – Updated to include information relating to male patients included in response to [September 2024 MHRA DSU Valproate Use in Men](#). Also see the BSW Together Valproate Safety Group webpage which hosts links to local and national resources that support safe valproate prescribing in existing and new patients: [Valproate Safety - Medicines](#).
- **New format** – [BSW Primary Care Guidelines for Pharmacological Management of Vitamin B12 Deficiency in Adults](#) – Updated and reformatted guidance.

Minor amendments to Netformulary

- A stoma leakage notification system ([Heylo®](#)) added as non-formulary.
- Use of [Miprosed® \(midazolam 5mg/ml oral solution\)](#) extended to include procedural sedation or premed in needle-phobic adults (off-label) **RED** TLS **GWH anaesthetists use only**
- [Heparin](#) for therapeutic treatment of VTE has been aligned with a **RED** TLS for BSW.
- Furosemide tablet **500mg** strength aligned with **RED** TLS for BSW.

What the BSW ICB formulary team are currently working on

- Writing a hypersalivation/drooling treatment pathway
- Reviewing position of daily Tadalafil 5mg
- Producing guidance for linzagolix [NICE TA996](#) for uterine fibroids
- Producing guidance for relugolix [NICE TA995](#) for prostate cancer
- Reviewing glaucoma guidance

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you



Bath and North East Somerset,
Swindon and Wiltshire Together

discover information you believe to be inaccurate or misleading, or for further information, email bswicb.formulary@nhs.net